Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in Advanced Cervical Carcinoma
NCT00389974Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2007
- Primary completion
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in cervical carcinoma, sponsored by National Cancer Institute. Primary endpoints: Objective Response Rate up to 2 years and Toxicity. Started Jan 2007; status: completed.
02
Drugs
sunitinib
03
Conditions
cervical carcinoma
Beyond the preview
Go deeper on NCT00389974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00389974.